[vc_row][vc_column width=»1/6″][/vc_column][vc_column css_animation=»fadeInUp» width=»2/3″][vc_custom_heading text=»Sarepta Acquires Investigational Gene Therapy for LGMD2A» use_theme_fonts=»yes»][vc_empty_space height=»10px»][vc_column_text]Sarepta Therapeutics has executed an exclusive license agreement for a gene therapy candidate that aims to treat limb-girdle muscular dystrophy type 2A (LGMD2A), the company announced.
The investigational therapy, called calpain 3 or CAPN-3, was developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, in Columbus, Ohio.
The deal followed a number of successful preclinical and safety studies led by Zarife Sahenk, MD, PhD, an attending neurologist at the hospital.
Mas información[/vc_column_text][/vc_column][vc_column width=»1/6″][/vc_column][/vc_row]